MarginsXMarginsX
Home › Markets › Health Care › RADX

Radiopharm Theranostics Limited (RADX)

RADX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7676
+1.00% on the day
Market cap
$11.1M
Nano cap
Revenue · 2026
$2.8M
-23.8% on 2025
Net income · 2026
-$57.0M
-2057.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1949257/000121390026105181/0001213900-26-105181-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerRADX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO yearNot reported by the screener
SEC CIK0001949257
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials · 2026

LineValue
Revenue$2.8M
Net income-$57.0M
Operating income-$56.8M
Net margin-2057.5%
Operating margin-2051.5%
Revenue growth-23.8%
Cash$4.1M
Total assets$60.1M
P/E (computed)Net income was not positive
P/S (computed)4.0×

Warning signs

Cash runway
0.9 months
$4.1M cash at June 30, 2026
Share count, 1 year
+49.9%
2025-06-30 to 2026-06-30
Going-concern doubt
Yes
20-F filed September 30, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions, along with other matters as set forth in Note 20(a)(iii), raise substantial doubt about the Group's ability to continue as a going concern."
20-F 2026-09-30
Cash and burn$4.1M cash; operating cash flow -$13.2M a quarter.Report 2026-06-30
Shares outstandingNo cover-page share count in XBRLCover page 2026-06-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-07-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton Audit Pty Ltd, Melbourne, AustraliaPCAOB Form AP 2026-10-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-06-30
$2.8M-$57.0M-$52.8M$4.1MNo debt tags$2.8M20-F 2026-09-30
FY 2025
2025-06-30
$3.6M-$38.3M-$36.6M$29.1MNo debt tags$3.6M20-F 2025-09-18
FY 2024
2024-06-30
$299K-$47.9M-$23.0M$18.6MNo debt tags$299K20-F 2025-09-18
FY 2023
2023-06-30
$292K-$34.6M-$23.2M$11.7MNo debt tags$292K20-F 2025-09-18

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-09-23
Latest annual report
ANNUAL REPORT
20-F2026-09-30
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-16

Source: SEC EDGAR submissions feed, 166 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-20.8%
1 month-36.7%
3 months-71.3%
Year to date-85.4%
1 year-83.3%
From 52-week high-92.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PTNPalatin Technologies Inc.$6.13-1.69%$10.9M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
HINDVyome Holdings Inc.$1.53-3.16%$10.7M
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
BIVIBioVie Inc.$1.08-4.42%$11.6M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M
BFRIBiofrontera Inc.$0.5700-18.58%$10.2M
CLRBCellectar Biosciences Inc.$1.01-11.40%$10.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier